Ahn Min Young, Hwang Jung Seok, Lee Su Bi, Ham Sun Ah, Hur Jinwoo, Kim Jun Tae, Seo Han Geuk
Department of Food Science and Biotechnology of Animal Products, Konkuk University, Seoul, South Korea.
Department of Food Science and Technology, Keimyung University, Daegu, South Korea.
PeerJ. 2017 Sep 14;5:e3808. doi: 10.7717/peerj.3808. eCollection 2017.
High mobility group box 1 (HMGB1) is a well-known damage-related alarmin that participates in cellular inflammatory responses. However, the mechanisms leading to HMGB1 release in inflammatory conditions and the therapeutic agents that could prevent it remain poorly understood. This study attempted to examine whether the herb, which is known to have anti-inflammatory property, can modulate cellular inflammatory responses by regulating HMGB1 release.
The murine macrophage RAW264.7 cells were treated with lipopolysaccharide (LPS) and/or a extract-loaded nanoemulsion (CLEN). The levels of released HMGB1, nitric oxide (NO) production, inducible NO synthase (iNOS) expression, and phosphorylation of mitogen-activated protein kinases were analyzed in RAW264.7 macrophages. The effects of CLEN on survival of endotoxemic model mice, circulating HMGB1 levels, and tissue iNOS expression were also evaluated.
We have shown that a nanoemulsion loaded with an extract from the rhizome regulates cellular inflammatory responses and LPS-induced systemic inflammation by suppressing the release of HMGB1 by macrophages. First, treatment of RAW264.7 macrophages with the nanoemulsion significantly attenuated their LPS-induced release of HMGB1: this effect was mediated by inhibiting c-Jun N-terminal kinase activation, which in turn suppressed the NO production and iNOS expression of the cells. The nanoemulsion did not affect LPS-induced p38 or extracellular signal-regulated kinase activation. Second, intraperitoneal administration of the nanoemulsion improved the survival rate of LPS-injected endotoxemic mice. This associated with marked reductions in circulating HMGB1 levels and tissue iNOS expression.
The present study shows for the first time the mechanism by which ameliorates sepsis, namely, by suppressing NO signaling and thereby inhibiting the release of the proinflammatory cytokine HMGB1. These observations suggest that identification of agents, including those in the herb , that can inhibit HMGB1 production and/or activity may aid the treatment of endotoxemia.
高迁移率族蛋白B1(HMGB1)是一种众所周知的与损伤相关的警报素,参与细胞炎症反应。然而,在炎症条件下导致HMGB1释放的机制以及能够预防其释放的治疗药物仍知之甚少。本研究试图检验已知具有抗炎特性的草药是否能通过调节HMGB1释放来调节细胞炎症反应。
用脂多糖(LPS)和/或载有提取物的纳米乳剂(CLEN)处理小鼠巨噬细胞RAW264.7细胞。分析RAW264.7巨噬细胞中释放的HMGB1水平、一氧化氮(NO)产生、诱导型NO合酶(iNOS)表达以及丝裂原活化蛋白激酶的磷酸化。还评估了CLEN对内毒素血症模型小鼠存活率、循环HMGB1水平和组织iNOS表达的影响。
我们已经表明,载有根茎提取物的纳米乳剂通过抑制巨噬细胞释放HMGB1来调节细胞炎症反应和LPS诱导的全身炎症。首先,用纳米乳剂处理RAW264.7巨噬细胞可显著减弱其LPS诱导的HMGB1释放:这种作用是通过抑制c-Jun氨基末端激酶激活介导的,这反过来又抑制了细胞的NO产生和iNOS表达。纳米乳剂不影响LPS诱导的p38或细胞外信号调节激酶激活。其次,腹腔注射纳米乳剂可提高LPS注射的内毒素血症小鼠的存活率。这与循环HMGB1水平和组织iNOS表达的显著降低有关。
本研究首次表明了改善败血症的机制,即通过抑制NO信号传导从而抑制促炎细胞因子HMGB1的释放。这些观察结果表明,鉴定能够抑制HMGB1产生和/或活性的药物,包括草药中的药物,可能有助于治疗内毒素血症。